Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Lagercrantz Year-end Report 2022/23

FOURTH QUARTER (1 JanuarY – 31 MarCH 2023) · Net revenue increased by 30% to MSEK 2,040 (1,575),of which organic growth amounted to 9%. · Operating profit (EBITA) increased by 29% to MSEK 343 (265),equivalent to an EBITA margin of 16.8% (16.8). · Profit after financial items (EBT) increased by 27% to MSEK 272 (214). · Cash flow from operating activities amounted to MSEK 418 (168). · Profit after taxes increased by 26% to MSEK 213 (169).   the financial year (1 APRIL 2022 – 31 march 2023) · Net revenue increased by 32% to MSEK 7,246 (5,482),of which organic

Penneo achieves 27% year-on-year ARR growth in Q1-2023

Company Announcement No. 22-2023Copenhagen, 16 May 2023Quarterly financial report for the period 1 January 2023 - 31 March 2023Q1-2023 performance highlights · ARR increased by 3.3M DKK to 74.2M DKK in Q1-2023, corresponding to 27% year-on-year (YoY) growth at the end of the quarter · ARR increase from Newbizz amounted to 2.0M DKK compared to 1.9M DKK in Q1-2022 · ARR increase from uplift amounted to 2.0M DKK compared to 1.6M DKK in Q1-2022  · ARR lost to churn amounted to 0.6M DKK compared to 0.4M DKK in Q1-2022 · ARR from foreign markets increased by 0.9M DKK compared

Investment Outlook: Falling inflation will provide support during slump

China’s economy is gearing up as the rest of the world slows down into a brief, shallow recession in which corporate earnings will hold up well. The investor community is restrained and cautiously positioned, while the corporate sector is thriving and in good shape. Our main economic scenario foresees a slowdown in 2023 and an acceleration during 2024. We support a neutral allocation at the asset class level, combined with good risk diversification, since volatility is likely to persist. “In this environment of positive and negative forces, since early autumn 2022 we have advocated a

Interim report January - March 2023

A robust core business – and strategic advances January 1 - March 31, 2023 · Net sales increased 26 percent to SEK 3,973 M (3,155). Adjusted for the acquisition of Koivunen, net sales increased 11 percent. Organic growth was 6 percent. · Net sales were positively impacted by 2 percent due to currency effects. · EBIT amounted to SEK 200 M (190) and the EBIT margin was 4.9 percent (5.9). EBIT was not impacted by any items affecting comparability during the quarter nor during the year-earlier period. · Adjusted EBIT amounted to SEK 227 M (225) and the adjusted EBIT margin was

SLP extends lease agreement with Veolia for 3,950 sqm and increases rent due to solar cell investment

SLP has extended a lease with Veolia by three years regarding the property Eskilstorp 14:97 in Malmö. Veolia has been a tenant since 2005 and rents the entire building of a total of 3,950 square meters. The existing lease, which expires on October 31, 2024, is thus extended by three years to October 31, 2027, at the same time an extended lease has been agreed to build a solar cell system on the property. The new annual rent is fully index regulated. Current lease is index regulated by 60%."It is gratifying that we have signed an extended agreement with Veolia while investing in

Announcement of Annual General Meeting in Akobo Minerals AB (publ)

The shareholders of Akobo Minerals AB (publ), company registration no 559148-1253 (the “Company”), are hereby invited to participate in the Annual General Meeting (“AGM”) to be held on June 19, 2023 at 10.00 am at the Company’s office at Södra Allégatan 13, Göteborg, Sweden. Participation Shareholders that wish to participate in the procedures at the AGM must: · on June 9, 2023, be recorded as shareholders in the share register kept by Euroclear Sweden AB (temporary registration for shareholders registered at the Norwegian CSD, Euronext Securities Oslo (formerly VPS) is made by

Neogap enrols first patient in Phase I/II clinical trial of personalised immunotherapy for colorectal cancer

Swedish biotechnology company Neogap Therapeutics, specialising in personalised immunotherapy for cancer treatment, has announced the successful enrolment of its first patient in a Phase I/II clinical trial targeting advanced colorectal cancer.Neogap has included the first patient in their first-in-human trial with the cell therapy product pTTL (personalised Tumour Trained Lymphocytes). Production of personalised EpiTCer[®] beads for the patient has been initiated. These beads play a crucial role in the pTTL therapy by facilitating the training of the T cells to recognise neoantigens and

Nordhealth AS: Q1/2023 results presentation

Please find attached the presentation of Nordhealth AS Q1/2023 results.The results will be presented in a live webcast and subsequent Q&A session with CEO Charles MacBain and CFO Mari Orttenvuori on the 16th of May 2023 at 13:00 CET. Please use the following link to attend: https://us02web.zoom.us/j/88442219363  The presentation will be recorded and made available on www.nordhealth.com For further information, please contact: Charles MacBain, CEO charles.macbain@nordhealth.com +44 75 3903 2200 Mari Orttenvuori, CFO mari.orttenvuori@nordhealth.com +358 46 8765 233

Synsam Group’s Q1 report 2023

Stronger organic growth (17.5 percent) and improved EBITDA margin compared with Q4 2022 - ”Cost programme starting to deliver according to plan”1 January - 31 March 2023 · Net sales amounted to SEK 1,411 million (1,186), up 19.0 percent. Organic growth totalled 17.5 percent (12.3) · Net sales from spectacles subscriptions increased 27 percent (18) · The gross margin was 76.6 percent (79.3) · EBITDA[[1]] rose to SEK 318 million (293) and the EBITDA margin was 22.3 percent (24.4) · EBITA amounted to SEK 171 million (178) and the EBITA margin was 12.0 percent (14.7) · EBIT

Thunderful Group Interim Report January–March 2023

A solid first quarter in a year with several exciting game releasesFirst quarter January–March 2023 · Net revenue increased 1.7 percent to 555.4 MSEK (546.0). · Operating profit (EBIT) increased 217.5 percent to 19.2 MSEK (6.0), corresponding to an operating margin of 3.1 percent (1.0). · Adjusted EBITDA increased 63.1 percent to 72.6 MSEK (44.5), corresponding to an adjusted EBITDA margin of 11.9 percent (7.3). · Adjusted EBITA increased 86.5 percent to 52.5 MSEK (28.1), corresponding to an adjusted EBITA margin of 8.6 percent (4.6). · Profit for the quarter amounted to 13.

Notice to Attend the Annual General Meeting in Scandinavian Real Heart AB

Press Release, 16 May 2023 The shareholders in Scandinavian Real Heart AB, reg. no. 556729–5588 (the "Company"), are hereby invited to the Annual General Meeting on Wednesday, 14 June 2023 at 15.00 at Best Western Plus Hotel Plaza, Kopparbergsvägen 10, 722 13 Västerås. Registration for the Meeting begins at 14:30.Right to participate in the Meeting, etc. Shareholders who wish to participate in the Meeting shall · be recorded in the share register kept by Euroclear Sweden AB no later than Monday, 5 June 2023, and · notify the Company their intention to participate no later than

Change in the YIT Management Team: Jennie Stenbom appointed EVP, Human Resources at YIT

YIT Corporation Stock Exchange Release 16 May 2023 at 8:15 a.m.Change in the YIT Management Team: Jennie Stenbom appointed EVP, Human Resources at YIT YIT Corporation has appointed Jennie Stenbom (M. Ed., eMBA) as Executive Vice President, Human Resources and member of the Group Management Team. She will start in her position in November 2023, at the latest. Tanja Kauhajärvi, Vice President, Employment Relations and Services, has been appointed as interim EVP of HR and member of the Management Team, starting on 16 May 2023. YIT’s current EVP, Human Resources Katja Ahlstedt has decided to

Flex LNG – Key information relating to the cash dividend to by paid by Flex LNG for the first quarter 2023

May 16, 2023Hamilton, Bermuda Key information relating to the cash dividend to be paid by Flex LNG Ltd. (Ticker: FLNG) for the first quarter 2023. Note to shareholders registered in Euronext VPS, the Norwegian Central Security Depository:Due to implementation of the Central Securities Depository Regulation (CSDR) in Norway, please note the information on the payment date to the shares registered in Euronext VPS below. Dividend amount: $0.75Declared currency: USD. Dividends payable to shares registered with Euronext VPS will be distributed in NOK.Last day including right:

Flex LNG – First Quarter 2023 Earnings Release

May 16, 2023Hamilton, Bermuda Flex LNG Ltd. (“Flex LNG” or the “Company”) today announced its unaudited financial results for the three months ended March 31, 2023. Highlights: *        Vessel operating revenues of $92.5 million for the first quarter 2023, compared to $97.9 million for the fourth quarter 2022.*        Net income of $16.5 million and basic earnings per share of $0.31 for the first quarter 2023, compared to net income of $41.4 million and basic earnings per share of $0.78 for the fourth quarter 2022.*        Average Time Charter Equivalent[1] (“TCE”) rate of

Atrium Ljungberg extends its contract with Ericsson in Lindholmen in Gothenburg

Atrium Ljungberg has extended its lease contract with Ericsson in Gothenburg, comprising more than 37,000 m[2] in Lindholmen. The two companies are going to work together to enhance their sustainability and energy conservation measures.Ericsson has been a tenant ever since Atrium Ljungberg acquired the property in Lindholmen in 2017. There are currently 2,400 people working in this property, which has 37,000 m[2] of offices and development spaces. Ericsson has now decided to extend its lease contract and will therefore remain an integral part of Lindholmen for the next four years. “We

Interim Report Q1, 2023

Strong eGFR Data from Positive NefIgArd Phase 3 Trial Readout“In March we announced that the global NefIgArd Phase 3 trial successfully met its primary endpoint, estimated glomerular filtration rate (eGFR), with a p value < 0.0001. Achieving this clinically relevant endpoint of kidney filtration capability represents a crowning achievement after well over a decade of pioneering work in IgA nephropathy. Nefecon, commercially available in the US and Europe under the brand name TARPEYO[®] and Kinpeygo[®] respectively, seems to be disease modifying, having shown both immediate and enduring

Webstep ASA: First quarter results 2023

Oslo, 16 May 2023: Webstep ASA reports revenues of NOK 277.2 million (NOK 233.0 million) and EBIT of NOK 25.2 million (NOK 23.9 million) for the first quarter. The EBIT margin in the quarter was 9.1 per cent (10.3 per cent). Net profit for the first quarter was NOK 18.8 million (NOK 17.8 million).Webstep had 557 employees at the end of first quarter, an increase of 65 employees compared to corresponding quarter last year.  – As we leave the first quarter behind, we can report robust revenue growth, stable EBIT and a growing Webstep workforce. Our consultants are considered key in

Health Canada accepts New Drug Submission for lecanemab as treatment for early Alzheimer’s disease

Stockholm, May 16, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (brand name in the U.S.: LEQEMBI™), an investigational anti-amyloid beta (Aβ) protofibril[1] antibody, for the treatment of early Alzheimer’s disease[2] with confirmed amyloid pathology in the brain.The NDA is based on the results of the Phase 3 Clarity AD study and the Phase 2b clinical study, which demonstrated that lecanemab treatment showed a reduction of clinical decline in early AD. Lecanemab selectively

Lundin Gold Announces Voting Results from Annual Meeting

VANCOUVER, BC, May 15, 2023 /CNW/ - Lundin Gold Inc. (TSX: LUG) (Nasdaq Stockholm: LUG) (OTCQX: LUGDF) ("Lundin Gold" or the "Company") is pleased to report the voting results from the Company’s 2023 Annual General Meeting of Shareholders (“Annual Meeting”), which was held today in Vancouver, British Columbia.   A total of 208,267,971 common shares were voted at the meeting, representing 88.05% of the votes attached to all the outstanding common shares.  Shareholders voted by ballot in favour of each of the items of business at the Annual Meeting as follows:   +------------------

TOMRA: Share purchase program for employees – Mandatory notification of trade

As part of TOMRA's share purchase program for employees, approved by the Annual General Meeting on 27 April 2023, TOMRA has sold 233,438 treasury shares to employees at a price equal to the closing market share price on Friday 12 May, i.e. NOK 170.80. Employees who keep their shares for one year will receive one share per five shares invested. Employees who have previously participated in the share purchase program have today been allotted 52,747 shares. After these transactions TOMRA holds 513,815 treasury shares. In connection with the share purchases program, the following PDMR

Clarification regarding announcement of senior management changes in SciBase

STOCKHOLM, SWEDEN, — May 15, 2023 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders hereby clarifies the May 15[th] announcement that Simon Grant will leave his position as CEO for personal reasons. Simon will transition out of his role over the next six months but will remain formally as CEO during this time. Simon Grant will also remain available to the Board in a consulting capacity after the end of the planned transition time.The Board has initiated the process to recruit a new CEO and will provide an update in

EIC Fund to Invest in Scandinavian Real Heart AB

Press Release, 15 May 2023 Realheart receives confirmation of an initial investment from the EIC of up to 3.5 MEUR.Today, we are pleased to announce that the European Innovation Council's (EIC) Accelerator intends to make an initial investment of up to 3.5 MEUR, equivalent to approximately 39 MSEK as part of Realheart’s next investment round. The investment means that the EIC considers Realheart's artificial heart to be groundbreaking and has the potential to reform healthcare for heart failure patients.  Formal confirmation is expected shortly. EIC is one of Europe's leading

Realheart Carries out new Issues of Shares of Maximum SEK 73 Million

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, SOUTH AFRICA OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Press Release, 15 May, 2023 The board of directors of Scandinavian Real Heart AB (publ) ("Realheart" or the "Company") has, subject to approval from the annual general meeting, decided to carry out a rights issue of up to 34,979,248 units with preferential rights for existing shareholders (the "Rights Issue"). The date for the annual general meeting has been moved to

There are no items matching the current filter
There are no more items matching the current filter
Back to top